Phaseline

Companies › Fortvita Biologics (USA)Inc.

Fortvita Biologics (USA)Inc.: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 1; Oncology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IBI3001–Phase 1Locally Advanced Solid TumorDec 2026
IBI3003–Phase 1Multiple MyelomaJun 2027
IBI3020
anti-CEACAM5 monoclonal antibody-drug conjugate
CEACAM5Phase 1Solid TumorsDec 2027
IBI3032–Phase 1Healthy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07120425IBI3032Phase 1HealthyOtherNov 2025
NCT06349408IBI3001Phase 1Locally Advanced Solid TumorOncologyDec 2026
NCT07336472IBI3003Phase 1Multiple MyelomaOncologyJun 2027
NCT06963281IBI3020Phase 1Solid TumorsOncologyDec 2027

Targets

CEACAM5 (1)

Companies with the same targets

Chongqing Precision Biotech Beijing Biotech Merck KGaA A2 Biotherapeutics Roche Bristol-Myers Squibb LaNova Medicines Genmab Harbour BioMed (Guangzhou) Kivu Bioscience

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.